Artificial intelligence approaches will help Alzheimer's disease in modern brain tests.

Published Date: 08 Mar 2023

While researchers have successfully detected symptoms of Alzheimer's disease using brain tests collected through their research, a team from the Massachusetts General Hospital Mob (MGH) recently...

Read Full News

Todays Updates


This Week on NeurologyLive® — November 16, 2026 Isabella Ciccone, MPH


Here's some of what is coming soon to NeurologyLive® this week.

Recognizing Early-Onset Alzheimer Disease and the Role of Blood Biomarkers Allison B. Reiss, MD, Isabella Ciccone, MPH


Allison B. Reiss, MD, associate professor of medicine at NYU Grossman Long Island School of Medicine discussed the often-overlooked early signs of early-onset Alzheimer disease.

FDA Approves Gefurulimab for Generalized Myasthenia Gravis Marco Meglio


Gefurulimab (Klygefa), a once-weekly, self-administered complement C5 inhibitor from Alexion and AstraZeneca, is now approved in the US for adults with AChR-antibody-positive generalized myasthenia gravis.

Cenobamate sNDA Seeks FDA Approval for Generalized Seizures Marco Meglio


A new FDA filing seeks to expand cenobamate's epilepsy indication to primary generalized tonic-clonic seizures, based on positive phase 3 trial data.

Benjamin Greenberg, MD, MHS, on Highlights From the 2026 Rare Neuroimmune Disorders Symposium Benjamin Greenberg, MD, Isabella Ciccone, MPH


The professor of neurology at UT Southwestern Medical Center discussed emerging trials, proposed changes to myelitis diagnostic criteria and nomenclature, and the unmet needs raised by patients at this year’s symposium.

Roche Launches Phase 2 TARBELA-AD Trial of NLRP3 Inhibitor in Alzheimer Disease Marco Meglio


A new global phase 2 trial, TARBELA-AD, will test RG6434, Roche's investigational oral NLRP3 inflammasome inhibitor, in adults with early symptomatic Alzheimer disease.

Trial Enrollment Complete for Pivotal Phase 2/3 Study of CB03-154 in ALS Marco Meglio


A pivotal phase 2/3 trial of Zhimeng Biopharma's CB03-154, an oral KCNQ2/3 potassium channel opener, has completed enrollment in amyotrophic lateral sclerosis.

Todays Updates


This Week on NeurologyLive® — November 16, 2026 Isabella Ciccone, MPH


Here's some of what is coming soon to NeurologyLive® this week.

Recognizing Early-Onset Alzheimer Disease and the Role of Blood Biomarkers Allison B. Reiss, MD, Isabella Ciccone, MPH


Allison B. Reiss, MD, associate professor of medicine at NYU Grossman Long Island School of Medicine discussed the often-overlooked early signs of early-onset Alzheimer disease.

FDA Approves Gefurulimab for Generalized Myasthenia Gravis Marco Meglio


Gefurulimab (Klygefa), a once-weekly, self-administered complement C5 inhibitor from Alexion and AstraZeneca, is now approved in the US for adults with AChR-antibody-positive generalized myasthenia gravis.

Cenobamate sNDA Seeks FDA Approval for Generalized Seizures Marco Meglio


A new FDA filing seeks to expand cenobamate's epilepsy indication to primary generalized tonic-clonic seizures, based on positive phase 3 trial data.

Benjamin Greenberg, MD, MHS, on Highlights From the 2026 Rare Neuroimmune Disorders Symposium Benjamin Greenberg, MD, Isabella Ciccone, MPH


The professor of neurology at UT Southwestern Medical Center discussed emerging trials, proposed changes to myelitis diagnostic criteria and nomenclature, and the unmet needs raised by patients at this year’s symposium.

Roche Launches Phase 2 TARBELA-AD Trial of NLRP3 Inhibitor in Alzheimer Disease Marco Meglio


A new global phase 2 trial, TARBELA-AD, will test RG6434, Roche's investigational oral NLRP3 inflammasome inhibitor, in adults with early symptomatic Alzheimer disease.

Trial Enrollment Complete for Pivotal Phase 2/3 Study of CB03-154 in ALS Marco Meglio


A pivotal phase 2/3 trial of Zhimeng Biopharma's CB03-154, an oral KCNQ2/3 potassium channel opener, has completed enrollment in amyotrophic lateral sclerosis.

Latest News

HTTP error: 503

News All Time

HTTP error: 503 HTTP error: 503 HTTP error: 503 HTTP error: 503 HTTP error: 503HTTP error: 503HTTP error: 503
Featured News
Featured Articles
Featured Events
Featured KOL Videos

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot